Global health care company, Sanofi, announced Wednesday that the US Food and Drug Administration (FDA) approved the pediatric hexavalent combination vaccine, VAXELIS™ .
VAXELIS was developed as part of a joint partnership between Sanofi and MSD (Merck) for use as a three dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday) for active immunization to prevent six infectious diseases–diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
Sanofi and MSD are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. Commercial supply will not be available in the U.S. prior to 2020.
- Chikungunya vaccine candidate receives FDA Fast Track Designation
- Zika vaccine: Nebraska researchers say potential vaccine would defend against Zika virus without producing antibodies
- Europe: Sanofi’s dengue vaccine gets approved
- Powassan vaccine induces potently neutralizing antibodies in mice: Study
- HIV: Experimental vaccine protects rhesus macaques from infection
- Lyme Disease vaccine candidate enters Phase 2 clinical development